1. Home
  2. SEER vs KZIA Comparison

SEER vs KZIA Comparison

Compare SEER & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seer Inc.

SEER

Seer Inc.

HOLD

Current Price

$1.70

Market Cap

97.3M

Sector

Health Care

ML Signal

HOLD

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

HOLD

Current Price

$8.63

Market Cap

93.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SEER
KZIA
Founded
2017
1994
Country
United States
Australia
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
97.3M
93.2M
IPO Year
2020
2002

Fundamental Metrics

Financial Performance
Metric
SEER
KZIA
Price
$1.70
$8.63
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$17.67
AVG Volume (30 Days)
203.2K
124.9K
Earning Date
05-12-2026
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
9.40
N/A
EPS
N/A
N/A
Revenue
$16,578,000.00
N/A
Revenue This Year
$2.14
N/A
Revenue Next Year
$25.90
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.99
N/A
52 Week Low
$1.65
$0.69
52 Week High
$2.41
$17.40

Technical Indicators

Market Signals
Indicator
SEER
KZIA
Relative Strength Index (RSI) 41.54 62.02
Support Level $1.69 $5.64
Resistance Level $1.97 $10.49
Average True Range (ATR) 0.04 0.80
MACD 0.00 0.14
Stochastic Oscillator 33.33 73.47

Price Performance

Historical Comparison
SEER
KZIA

About SEER Seer Inc.

Seer Inc is a life sciences company, develops and commercializes products to decode the biology of the proteome. The company offers Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company operates in China, Australia, Eastern Europe, Israel, Japan and South Africa.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: